JFJonathan A. Forsberg

Jonathan A. Forsberg

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Jonathan A. Forsberg has a total of 68 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Bone Mineral Density After Transfemoral Amputation Osseointegration: A 2-Year Longitudinal Analysis

    by Benjamin K. Potter, Julio Rivera, Bradford D. Hendershot, Ashley B. Bozzay, Jason M. Souza, Jonathan A. Forsberg

    Background:Bone mineral density (BMD) loss is common after lower extremity amputation, but skeletal adaptation after transfemoral osseointegration remains poorly characterized. This study evaluated longitudinal changes in femoral neck BMD after transfemoral osseointegration and identified factors associated with BMD change. Methods:This single-center retrospective study included patients who underwent unilateral or bilateral transfemoral osseointegration and completed 2-year follow-up. Femoral neck BMD was assessed at baseline and at 3, 6, 12, and 24 months postoperatively. The primary outcome was change in femoral neck BMD from baseline to 24 months. Associations between BMD change and patient characteristics, gait-derived biomechanical loading measures, and patient-reported outcomes were evaluated using correlation analyses and multivariable linear regression. Results:A total of 37 patients were included (23 unilateral and 14 bilateral). BMD in the osseointegrated limb decreased during the first postoperative year, reached a nadir at 12 months, and recovered toward baseline by 24 months, while the contralateral (non-osseointegrated) limb remained stable. Changes in BMD were not associated with age, time since amputation, laterality, biomechanical loading measures, or patient-reported outcomes (all p > 0.05). Higher adjusted BMI was associated with greater decreases in BMD (β = –0.0078 per unit increase, p = 0.021), with consistent findings across correlation and multivariable analyses. Conclusion:BMD declines during the first postoperative year after transfemoral osseointegration but recovers toward baseline by 2 years, with no evidence of sustained bone loss. Changes in BMD are not associated with self-reported functional or gait-derived biomechanical measures, suggesting that skeletal adaptation occurs independently of functional recovery in the early postoperative period. Higher BMI may be associated with less favorable skeletal adaptation.

  • Do amputation characteristics predict outcomes measures and infections after osseointegration surgery?

    by Julio A. Rivera, Ashley B. Bozzay, Jason M. Souza, Benjamin K. Potter, Jonathan A. Forsberg

    Objective: To determine which patient characteristics are associated with patient-reported outcomes and infection outcomes after transfemoral osseointegration surgery. Methods: Design: Single-center retrospective study. Setting: Walter Reed National Military Medical Center, Bethesda, MD. Patient Selection Criteria: Patients who underwent unilateral or bilateral transfemoral osseointegration surgery and completed 2-year follow-up. Outcome Measures and Comparisons: Baseline patient characteristics (age at primary amputation, time living with limb loss, residual femur length, age at osseointegration surgery, and limb-loss–adjusted body mass index [BMI]) were evaluated as predictors of change in patient-reported outcomes from baseline to 2-year follow-up (Q-TFA domains, PROMIS domains, and patient-reported prosthesis use) and of infection outcomes (any infection and number of infections), using generalized linear models with AIC-guided backward elimination and adjustment for amputation laterality (unilateral vs bilateral). Results: There were 54 patients included (37 unilateral and 17 bilateral) who completed 2-year follow-up. The unilateral cohort had a mean age of 41.1 years (range, 24–72) and was predominantly male (33 males, 4 females), whereas the bilateral cohort had a mean age of 33.6 years (range, 26–41) and consisted entirely of male patients. Adjusted BMI best predicted changes in Q-TFA Global (R 2 = 0.06, F(1,48) = 3.8, p = 0.05) and Problem scores (R 2 = 0.07, F(1,48) = 4.7, p = 0.03), as well as PROMIS Pain Interference (R 2 = 0.25, F(1,50) = 17.8, p < 0.001) and Pain Behavior scores (R 2 = 0.26, F(1,50) = 18.7, p < 0.001) between baseline and 2-year follow-up. Adjusted BMI also best predicted changes in Q-TFA Prosthetic Use, PROMIS Physical Function, and prosthesis use time. Adjusted BMI was the strongest predictor of the number of infections. Conclusion: Among unilateral and bilateral transfemoral amputees undergoing osseointegration surgery with 2-year follow-up, lower adjusted BMI was associated with improved patient-reported outcomes and fewer infection events. Differences between unilateral and bilateral amputees suggest amputation laterality may modify postoperative outcomes. Level of Evidence: Therapeutic Level III

  • The Transfemoral and Transhumeral OPRA (Osseoanchored Prostheses for the Rehabilitation of Amputees) Osseointegration Technique

    by Ashley B. Bozzay, Benjamin K. Potter, Jonathan A. Forsberg

    Background: The transfemoral or transhumeral Osseoanchored Prostheses for the Rehabilitation of Amputees (OPRA) osseointegration technique is indicated in patients with transfemoral or transhumeral amputations who have difficulty with use of a conventional socket and traditional prosthesis. Augmentations to the procedure, such as targeted muscle reinnervation (TMR) and/or a regenerative peripheral nerve interface (RPNI), serve to enhance function (in the case of TMR) and/or improve residual-limb neuropathic pain (in the case of combined TMR and RPNI) in the same patient population. Description: This surgical technique is typically performed as a 2-stage procedure with approximately 6 weeks to 3 months between stages to allow for adequate bone graft healing and osseointegration of the fixture to the surrounding bone. Stage 1: Position the fluoroscopy machine on the opposite side of the patient. Because all transfemoral amputations rest in slight external rotation, obtain a true anteroposterior view of the hip, note the rotation of the C-arm, and subtract 90° to obtain a true lateral radiograph. Utilizing the prior incision, develop cutaneous flaps and distally approach the bone of the residual limb. Most patients will require a thighplasty procedure to manage excess soft tissues. Thighplasty may be performed during stage 1 and/or stage 2. The previous muscle platform is encountered, and an osteotomy is performed perpendicular to the long axis of the bone. A bone graft (5 to 10 cc) is harvested from the proximal humerus or femur with use of a curved curet. Next, the bone is progressively reamed under fluoroscopic guidance until the cortex is encountered. Reaming is done by hand in order to avoid thermal necrosis. Care is taken to avoid reaming too much of the anterior cortex proximally. A tap is selected that is 1.5 mm thicker than the final reamer, and the bone is tapped with use of the line-to-line technique to the size of the fixture. In cases of soft bone, we choose to under-tap by 0.5 mm prior to inserting the fixture. The final OPRA implant is inserted into the bone. The central screw is inserted and tightened to 80 N-cm. The healing cylinder is placed, which serves as a mold for the bone graft, and the previously harvested bone graft is packed around it. The graft screw and large washer are placed to compress the bone graft. Placement of the implant and healing components is confirmed on biplanar fluoroscopy. Stage 2: Through a limited incision, the graft screw and components are removed. The bone graft is inspected for proper integration around the distal fixture. The purpose of the bone graft is to provide a broad, vascular base onto which the full-thickness skin graft heals. Then, cutaneous flaps are elevated and fasciotomies are made. A medial or lateral-based thighplasty can be performed to address any soft-tissue redundancies that may prevent a tight soft-tissue platform at closure. The fascia from the muscle is attached to the bone approximately 1.5 cm proximal to the distal bone with use of 0 Vicryl (Ethicon) suture. A purse-string stitch is utilized to further reinforce the myoplasty. If there is muscle herniation, utilize 0 Vicryl suture to perform side-to-side closure of the fascia over the underlying muscle. The cutaneous flap is thinned, and a suitable position for the aperture is identified on the superior flap. A 9-mm (for transfemoral) or 6-mm (for transhumeral) punch-biopsy tool is utilized to create the skin penetration site or aperture. With use of the abutment as a guide, the fat layer is removed to expose the undersurface of the dermis. The flap is then rotated into position atop the distal femur and bone graft with use of a series of 2-0 Vicryl sutures. The abutment is then inserted, and the internal threads are cleaned with an angiocatheter and saline solution. The threads are dried with use of cotton-tip applicators, and the abutment screw is tightened by hand (it is further tightened to 12 Nm at the first follow-up visit). The incision is closed with 2-0 Monocryl (Ethicon), 3-0 Monocryl, and a self-adhering mesh with 2-octylcyanoacrylate liquid adhesive. Topical nitroglycerin is placed around the aperture and sealed with an antimicrobial foam dressing bolster. The bolster dressing is held in place with use of a bolster that is shaped like a skateboard wheel. The patient avoids range of motion of the limb for 5 days to allow for healing of the aperture. Peripheral nerve management: Terminal neuromas are identified. Mixed sensory and motor nerve branches to neighboring muscle targets are identified with use of a handheld nerve stimulator and then are preserved. The terminal neuroma is transected to freshly bleeding fascicles, and the newly freshened nerve end is coapted to a newly divided nearby motor nerve of a deliberately de-innervated muscle motor branch for TMR. This step is performed with a single centralizing 8-0 suture and several 6-0 epineurial to epimysial sutures. For RPNI, the transected nerve is sutured to the harvested segments of muscle from the distal lower leg with use of 8-0 epineurial-to-epimysial sutures that are then reinforced with 4-0 Vicryl sutures. Vascularized RPNI is an alternative technique performed by tunneling the nerve through and embedding its ending in a neighboring muscle belly. Fibrin glue may also be utilized to reinforce the suture fixation. Closure: At the end of the above procedures, meticulous hemostasis is obtained with electrocautery and thrombin spray. The wound is copiously irrigated. One gram of vancomycin powder is placed into the wounds to decrease infection risk and the severity of heterotopic ossification. The residual limb is irrigated, a drain is placed laterally, and the soft tissues are closed sequentially in a standard layered fashion to prevent bursa formation. Alternatives: Alternative treatments include local soft-tissue rearrangement, such as thighplasty that allows for improvement in socket use. Additionally, multiple percutaneous implant systems exist for clinical use internationally. Each of these implants utilizes osseointegration biology to create a stable bone-implant interface for direct skeletal attachment while attempting to avoid complications such as infection and loosening. Rationale: Direct skeletal attachment of a terminal prosthesis to a bone-anchored implant allows amputees who have previously had trouble with socket wear to experience improved function, mobility, and quality of life. Expected Outcomes: A prospective 5-year follow-up of patients undergoing the transfemoral OPRA osseointegration technique demonstrated significant improvements in patient-reported outcome measures. However, increases in deep infections and mechanical complications remained a concern (11 patients had 14 deep infections, 15 patients had mechanical complications, and 4 fixtures were removed) 3 . With transhumeral osseointegration, the 2-year implant survival rate was 100%, with no infection-related complications. Cellulitis related to skin penetration was easily managed with nonoperative aperture hygiene and/or oral antibiotic therapy. Important Tips: Appropriate soft-tissue management is the most important part of any osseointegration procedure. A 2-stage procedure ensures a well-vascularized bone surface to accept a full-thickness skin graft and ensures that there is no relative motion at the skin-implant interface. The goal is to produce a stable soft tissue platform with minimal tissue movement at the skin penetration site (also called aperture or stoma). Acronyms and Abbreviations: TMR = targeted muscle reinnervation RPNI = regenerative peripheral nerve interface RLP = residual-limb pain


  • Estimating the 5-Year Publication Potential for Grant Awardees: Analysis of the Peer Reviewed Orthopaedic Research Program

    by Ashley B Anderson, Julio Rivera, Clare F Grazal, Scott M Tintle, Benjamin K Potter, Jonathan F Dickens, Jonathan A Forsberg

    Introduction: Research-funding agencies are sometimes criticized for their ineffective review of grant proposals and for prioritizing competition for grants over project outcomes. Deficiencies in the review process for grants may limit the diversity of a program’s applicant pool and restrict opportunities for publication. Our study asked what features of Peer Reviewed Orthopaedic Research Program (PRORP) grants and grant recipients were associated with successful grant outcomes, with success defined as publication of results within 5 years of receipt of funding. Materials and Methods: Using data from all PRORP grants from 2009 to 2017, we built machine-learned predictive models to estimate publication within 5 years. Features included in the analysis were principal investigator characteristics (sex, degree, and institution type) and grant characteristics (research grant mechanism, primary and secondary research topics, and amount awarded). We evaluated model performance using calibration plots and then determined the models’ discriminatory ability by estimating the area under the receiver operator curve and c-statistic. Then we used Brier scores to obtain an overall assessment of each model’s accuracy. We ultimately selected 1 model for administrative use based on its performance measures. Results: The Bayesian generalized linear model performed best (area under the curve, 0.82 [95% CI, 0.68-0.95]; Brier score, 0.17 [95% CI, 0.10-0.23]) and therefore was selected. It showed administrative utility in decision curve analysis. Awardee features most strongly associated with publication were previous award winner (no), principal investigator specialty (anesthesiology), sex (male), degree (PhD), and institution type (university). Grant features most strongly associated with publication were primary topic (stem cell therapy and chemoprevention), secondary topic (biologics), research type (in vitro study and animal validation), award mechanism (translational research), award amount > median amount ($598,000), and award years 2010-2011. Conclusions: This model can aid the PRORP in identifying awardees who will successfully publish, and funding agencies and policymakers likewise can use it to apportion grants in a manner that promotes diversity across the applicant pool.

  • Does Transhumeral Osseointegration After Amputation Improve Patient-reported Outcomes and Prosthesis Use?

    by Jonathan A. Forsberg, Julio A. Rivera, Ashley B. Anderson, Jason M. Souza, Benjamin K. Potter

    Background: Individuals who have undergone transhumeral amputation often have difficulty wearing conventional socket-based prostheses, leading to frequent dissatisfaction and abandonment of the prosthesis. Osseointegration surgery may alleviate or mitigate many of these issues by providing a firm, reliable attachment between the humerus and the prosthesis, potentially leading to better functionality and quality of life; however, it is unclear whether the risks inherent to transdermal bone-anchored implants outweigh the potential functional benefits. Questions/purposes: (1) Were there improvements in patient-reported outcome measures at 2 years among patients with transhumeral amputations undergoing osseointegration compared with presurgical function in those patients? (2) What was the frequency and severity of complications related to the osseointegration procedures? Methods: Between October 2016 and April 2021, we recruited 12 active duty service members, retirees, and healthcare beneficiaries to undergo transhumeral osseointegration surgery using the Osseointegrated Prostheses for the Rehabilitation of Amputees (OPRA) implant system in this prospective, observational study. The primary indication was difficulty wearing a traditional socket-based prosthesis after extended efforts to do so and a residual humerus of ≥ 10 cm, while the exclusion criteria were a residual humerus of<≤ 10 cm, BMI > 35 kg/m2, severe peripheral vascular disease including diabetes, taking immunosuppressant medications, pregnancy, and those unable to sign their own consent. A total of 24 people were screened, and 12 met the inclusion criteria. All 12 participants (all men with a mean ± SD age of 38 ± 12 years) completed the minimum follow-up time of 2 years for this analysis. The majority of the patients’ mechanism of injury was blast (10 of 12) followed by motor vehicle collision (2 of 12). All 12 participants in this prospective FDA early feasibility study underwent both Stage 1 (fixture implantation into the humerus) and Stage 2 (muscle and skin fashioning) surgery, and none was lost to follow-up at a minimum of 2 years after April 2021. Participants were asked to complete the DASH questionnaire, the Defense and Veterans Pain Rating Scale (DVPRS), and items from three domains of the Patient-Reported Outcomes Measurement Information System (PROMIS) before surgery and at 3, 6, 12, and 24 months after the second stage of the procedure. They also reported their prosthetic use time in hours in a day and days in a week. We recorded the frequency of complications related to the procedure, including soft tissue, mechanical, and infectious complications. Results: Participants had improvements in mean ± SD DASH scores between baseline (36 ± 23) and a minimum of 2-year follow-up (19 ± 13) (mean difference 17 [95% confidence interval (CI) 1 to 33]; p = 0.04), and they had increases in days per week of prosthetic use time between baseline (4 ± 3) and the 2-year follow-up (7 ± 1) (mean difference 3 [95% CI 1 to 5]; p = 0.02). We found no difference in the physical function score (p = 0.47), pain interference score (p = 0.46), pain behavior score (p = 0.16), the DVPRS (p = 0.58), or prosthetic use time in hours per day (p = 0.09). We found no superficial soft tissue infections, but we did observe two soft tissue complications, two mechanical complications, and one skin penetration aperture complication consisting of marginal necrosis that healed uneventfully. No patients who developed these complications returned to the operating room. Conclusion: This FDA early feasibility study found notable improvements in patients’ DASH scores and prosthetic use, suggesting that transhumeral osseointegration using the OPRA implant system is a promising approach for patients who have lost a limb. Complications were relatively minor and treatable, and no infections were seen, which is consistent with prior evidence that infections may be considerably less frequent for those living with transhumeral amputation than for those who have undergone osseointegration for lower extremity amputations. As such, the technique appears to be promising in this patient population, with the caveat that this is a preliminary study in a very small selected patient population. These data can be used to justify the use of the OPRA implant system in appropriate patients living with transhumeral amputations, help inform future clinical trial design, as well as to support a Premarket Approval application with the FDA. Level of Evidence: Level II, therapeutic study.


  • Top Cited Papers

    What Functional Outcomes Can Be Expected With Osseointegrated Prostheses in Transfemoral Amputations?

    by Benjamin K. Potter, Julio A. Rivera, Ashley B. Anderson, Jason M. Souza, Jonathan A. Forsberg

    Background: Individuals who have undergone transfemoral amputation often have difficulty donning and utilizing a conventional socket prosthesis. Osseointegrated prostheses may alleviate certain issues, potentially resulting in better outcomes, but few prospective studies have either evaluated these outcomes or quantified the purported benefits. Questions/purposes: (1) Did patient-reported outcome measures improve between baseline and 2-year follow-up among those who underwent osseointegration surgery after transfemoral amputation? (2) What was the frequency and severity of early complications related to the osseointegration procedures? (3) What was the minimum clinically important difference (MCID) in a global patient-reported outcome measure in this patient population? Methods: Between October 2017 and October 2023, we recruited 41 participants to undergo transfemoral osseointegration surgery treated with the Osseointegrated Prostheses for the Rehabilitation of Amputees implant system for patients who had trouble utilizing traditional, socket-based prostheses. Of those, 5% (2 of 41) did not undergo surgery, 2% (1 of 41) were lost to follow-up, and 2% (1 of 41) died before the final 2-year follow-up, leaving 90% (37 of 41) for analysis in this prospective, observational trial. Participants were asked to complete the validated Questionnaire for Persons with a Transfemoral Amputation (Q-TFA) and the Patient-Reported Outcomes Measurement Information System (PROMIS) questionnaire before surgery as well as 3, 6, 12, and 24 months after the two-stage procedure. Thirty-seven participants (three women and 34 men; mean ± SD age 38 ± 10 years) reached the 24-month follow-up visit, and four patients were withdrawn. We tabulated the frequency and types of surgical complications that patients experienced and calculated the anchored-based MCID for the Q-TFA global score (0 to 100 maximum). The Q-TFA’s global score is generated based on answers to three questions: “How would you summarize your level of function with your current prosthesis?”, “How would you summarize the problems you experience with your current prosthesis?”, and “How would you summarize your overall situation as an amputee?” Using the sum of the numerical scores for the three questions, we found the difference between the baseline and the final follow-up for the participants. Then, we took the first quartile of the difference to represent the median change in the lower 25% of the data and used this value as our MCID. Results: Scores in the study group improved in nearly all domains of the Q-TFA and PROMIS, including those related to prosthetic use, prosthetic mobility, and physical function (all p < 0.05). Patients developed superficial infections in 29% (15 of 51) of implanted limbs, all of which were treated successfully with antibiotics alone; 7 patients developed deep infections, only 1 of which involved the bone and implant. The anchor-based MCID in the Q-TFA global score was calculated as 17 of 100 for this study population. Conclusion: Functional patient-reported outcomes improved in multiple domains among our patient cohort who underwent osseointegration surgery after transfemoral amputation, demonstrating the promise of this technology for patients with unsatisfactory function using conventional, socket-based prostheses. Infections and other complications were lower than in prior studies of osseointegration following limb loss. The novel MCID that we report can be used to determine whether patients have clinically important improvement in future osseointegration surgery studies comparing results between different implants, surgical techniques, and patient populations. Level of Evidence: Level II, therapeutic study.


  • Do Fellowship-educated Military Orthopaedic Oncologists Who Practice in Military Settings Treat a Sufficient Volume of Patients to Maintain Their Oncologic Expertise?

    by Ashley B. Anderson, Julio A. Rivera, James H. Flint, Jason Souza, Benjamin K. Potter, Jonathan A. Forsberg

    Background: Fellowship-trained orthopaedic oncologists in the US military provide routine clinical care and also must maintain readiness to provide combat casualty care. However, low oncologic procedure volume may hinder the ability of these surgeons to maintain relevant surgical expertise. Other low-volume specialties within the Military Health System (MHS) have established partnerships with neighboring civilian centers to increase procedure volume, but the need for similar partnerships for orthopaedic oncologists has not been examined. The purpose of this study was to characterize the practice patterns of US military fellowship–trained orthopaedic oncologists. Questions/purposes: We asked the following questions: (1) What are the diagnoses treated by US military fellowship–trained orthopaedic oncologists? (2) What are the procedures performed by US military fellowship–trained orthopaedic oncologists? Methods: We queried the Military Data Repository, a centralized repository for healthcare data for all healthcare beneficiaries (active duty, dependents, and retirees) within the Defense Health Agency using the MHS’s Management and Reporting Tool for all international common procedure taxonomy (CPT) codes and ICD-9 and ICD-10 codes associated with National Provider Identifier (NPI) numbers of active duty, military fellowship–trained orthopaedic oncologists. Fellowship-trained orthopaedic oncologists were identified by military specialty leaders. Then, we identified all procedures performed by the orthopaedic oncologist based on NPI numbers for fiscal years 2013 to 2022. We stratified the CPT codes by top orthopaedic procedure categories (such as amputation [performed for oncologic and nononcologic reasons], fracture, arthroplasty, oncologic) based on associated ICD codes. These were then tabulated by the most common diagnoses treated. Results: Thirteen percent (796 of 5996) of the diagnoses were oncologic, of which 45% (357 of 796) were malignant. Forty-four percent (158 of 357) of the malignancies were primary and 56% (199 of 357) were secondary; this translates to an average of 2 patients with primary and 2.5 patients with secondary malignancies treated per surgeon per year. During the study period, nine orthopaedic oncologists performed 5996 orthopaedic procedures, or 74 procedures per surgeon per year. Twenty-one percent (1252 of 5996) of the procedures were oncologic; the remaining procedures included 897 arthroplasties, 502 fracture-related, 275 amputations for a nononcologic indication, 204 infections, 142 arthroscopic, and 2724 other procedures. Conclusion: Although military orthopaedic oncologists possess expert skills that are directly translatable to combat casualty care and operational readiness, within MHS hospitals they treat relatively few patients with oncologic diagnoses, and less than one-half of those involve malignancies. Clinical Relevance: Despite postgraduation procedure volume raining stable over the last decade, it is unknown how many new patient visits for oncologic diagnoses and how many corresponding tumor procedures are necessary to maintain competence or build confidence after musculoskeletal oncology fellowship training. It is important to note that there are no military orthopaedic oncology fellowships, and all active duty orthopaedic oncologists undergo training at civilian institutions. Military-civilian partnerships with high-volume cancer centers may enable military orthopaedic oncologists to work at civilian cancer centers to increase their oncologic volume to ensure sustainment of operationally relevant knowledge, skills, and abilities and improve patient care and outcomes.


  • Team Approach: Osseointegration Amputation Surgery

    by Ashley B. Anderson, Jason M. Souza, Lisa Prasso, Shannon Ford, Julio A. Rivera, Louise Hassinger, Tawnee Sparling, Jonathan A. Forsberg, Benjamin K. Potter

    Update: This article was updated on August 7, 2024 because of a previous error. On page 1, the last sentence of the abstract that had read “We hope this model will service as an implant-agnostic guide to others seeking to development an osseointegration center of excellence.” should have read “We hope this model will serve as an implant-agnostic guide to others seeking to develop an osseointegration center of excellence.” now reads “We hope this model will serve as an implant-agnostic guide to others seeking to develop an osseointegration center of excellence.”. An erratum has been published: JBJS Rev. 2024;12(8):e24.00048ER. » The purpose of this article was to review the multidisciplinary, team-based approach necessary for the optimal management of patients with limb loss undergoing osseointegration surgery. » In this study, we describe the interdisciplinary process of screening, counseling, and surgical and rehabilitation considerations with an emphasis on principles rather than specific implants or techniques. » Integrated perioperative management and long-term surveillance are crucial to ensure the best possible outcomes. » We hope this model will serve as an implant-agnostic guide to others seeking to develop an osseointegration center of excellence.


  • Open Access

    Deep Learning and Multimodal Artificial Intelligence in Orthopaedic Surgery

    by Anthony Bozzo, James M. G. Tsui, Sahir Bhatnagar, Jonathan Forsberg

    This review article focuses on the applications of deep learning with neural networks and multimodal neural networks in the orthopaedic domain. By providing practical examples of how artificial intelligence (AI) is being applied successfully in orthopaedic surgery, particularly in the realm of imaging data sets and the integration of clinical data, this study aims to provide orthopaedic surgeons with the necessary tools to not only evaluate existing literature but also to consider AI's potential in their own clinical or research pursuits. We first review standard deep neural networks which can analyze numerical clinical variables, then describe convolutional neural networks which can analyze image data, and then introduce multimodal AI models which analyze various types of different data. Then, we contrast these deep learning techniques with related but more limited techniques such as radiomics, describe how to interpret deep learning studies, and how to initiate such studies at your institution. Ultimately, by empowering orthopaedic surgeons with the knowledge and know-how of deep learning, this review aspires to facilitate the translation of research into clinical practice, thereby enhancing the efficacy and precision of real-world orthopaedic care for patients.


  • Open Access

    Lifetime cost-effectiveness analysis osseointegrated transfemoral versus socket prosthesis using Markov modelling

    by Jeffrey D. Voigt, Benjamin K. Potter, Jason Souza, Jonathan Forsberg, Danielle Melton, Joseph R. Hsu, Benjamin Wilke

    Aims: Prior cost-effectiveness analyses on osseointegrated prosthesis for transfemoral unilateral amputees have analyzed outcomes in non-USA countries using generic quality of life instruments, which may not be appropriate when evaluating disease-specific quality of life. These prior analyses have also focused only on patients who had failed a socket-based prosthesis. The aim of the current study is to use a disease-specific quality of life instrument, which can more accurately reflect a patient’s quality of life with this condition in order to evaluate cost-effectiveness, examining both treatment-naïve and socket refractory patients.Methods: Lifetime Markov models were developed evaluating active healthy middle-aged male amputees. Costs of the prostheses, associated complications, use/non-use, and annual costs of arthroplasty parts and service for both a socket and osseointegrated (OPRA) prosthesis were included. Effectiveness was evaluated using the questionnaire for persons with a transfemoral amputation (Q-TFA) until death. All costs and Q-TFA were discounted at 3% annually. Sensitivity analyses on those cost variables which affected a change in treatment (OPRA to socket, or socket to OPRA) were evaluated to determine threshold values. Incremental cost-effectiveness ratios (ICERs) were calculated.Results: For treatment-naïve patients, the lifetime ICER for OPRA was $279/quality-adjusted life-year (QALY). For treatment-refractory patients the ICER was $273/QALY. In sensitivity analysis, the variable thresholds that would affect a change in the course of treatment based on cost (from socket to OPRA), included the following for the treatment-naïve group: yearly replacement components for socket > $8,511; cost yearly replacement parts OPRA < $1,758; and for treatment-refractory group: yearly replacement component for socket of > $12,467.Conclusion: The use of the OPRA prosthesis in physically active transfemoral amputees should be considered as a cost-effective alternative in both treatment-naïve and treatment-refractory socket prosthesis patients. Disease-specific quality of life assessments such as Q-TFA are more sensitive when evaluating cost-effectiveness.Cite this article: Bone Jt Open 2024;5(3):218–226.